The global regenerative medicine market is projected to reach $39 million by 2030, up from $8.2 million in 2019, according to market research company P&S Intelligence.
Biologics
Orthopedic biotechnology company Ortho Regenerative Technologies focused on developing soft tissue repair regenerative technology in 2020. For 2021, that development is expected to grow.
UC Davis Health in Sacramento, Calif., on March 1 announced the launch of the first FDA-approved human clinical trial using stem cells before birth to treat spina bifida, a defect that occurs when the spine and spinal cord do not…
Patients injected with stem cells derived from their own bone marrow saw improvement in motor functions after spinal cord injuries, a study from New Haven, Conn.-based Yale University found.
Butte-based Montana Orthopedics' Anthony Russo, MD, became the first spine surgeon in the U.S. to implant Kore Fiber, a demineralized cortical fiber allograft.
Advertisement
DiscGenics, a biopharmaceutical company focused on regenerative therapies for spinal conditions, has completed construction on its 25,000-square-foot headquarters in Salt Lake City.
Orthobiologics company Bioventus launched its initial public offering, according to a Feb. 4 news release.
Orthobiologics company Bioventus is hoping to secure $100 million for its proposed stock offering, according to WRAL Tech Wire.
Richmond-based OrthoVirginia's Adam Crowl, MD, performed the first spinal fusion in clinic with the ViBone Moldable cell bone matrix, according to a Jan. 12 news release.
Peter Fields, MD, director of OrthoRegen in Santa Monica, Calif., is offering a stem cell therapy that combines four regenerative orthopedic procedures.